Social Anxiety Disorders (SAD) Therapeutics – Pipeline Assessment and Market Forecasts to 2019

Jan. 20, 2012 - PRLog -- GlobalData estimates that the global Social Anxiety Disorder (SAD) therapeutics market was worth $579.8m in 2011, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 1.6% over the next eight years to reach $645m by 2019. This low growth is primarily attributed to the presence of generic competition in the SAD market, which has a low cost of therapy. Low treatment-seeking behavior and diagnosis rates currently exist in the market. However, there has been an increase in disease awareness among patients and physicians, which will add to the growth of the market. SAD is now being recognized as a disorder that cannot be neglected. Several studies by both governmental and nongovernmental organizations have analyzed the loss of workforce due to SAD and are working towards increasing awareness.

GlobalData’s research indicates that the current market is served by US Food and Drug Administration
(FDA)-approved drugs, off label drugs and alternative therapies such as cognitive behavioral therapy. The onset of SAD usually occurs in adolescence. To avoid treatment emergent adverse events, physicians opt for non-pharmacological treatments over medication. The current treatment options include Selective Serotonin Re-uptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), benzodiazepines, and Monoamine Oxidase Inhibitors (MOIs). All these treatment options have moderate safety and efficacy profiles and the current drugs in the SAD therapeutics market are generics with a low cost of therapy.

The SAD therapeutics pipeline has five molecules in development. There are no products in Phase III. The SAD therapeutics pipeline contains molecules in the early stage of development that are not expected to impact the market in the forecast period. There are three products in Phase II and two in Phase I. The current competition in the market is strong with generic products available as treatment options. With no launches due in the forecast period and the prevailing generic competition, the competition in the future market is not expected to intensify through 2019

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

The SAD therapeutics market has moderate unmet need. The therapies which are available for the treatment of SAD have shown moderate efficacy and safety profiles, which has led to moderate unmet need in the market. Patients experiencing symptoms of SAD do not generally perceive it as a disorder and do not actively seek treatment. Patients avoid treatment due to fear and social stigma. The currently available diagnostic tools for SAD diagnosis are not effective and this leads to poor diagnosis rates. Overall, the SAD therapeutics market has treatment options that are satisfying patients, but there are still low treatment-seeking behavior and diagnosis rates.

GlobalData, the industry analysis specialist, has released its new report, “Social Anxiety Disorder (SAD) Therapeutics – Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global SAD market. The report identifies the key trends shaping and driving the global SAD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global SAD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Soci...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.